

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Pharmala Biotech Holdings Inc. (the "Issuer").

Trading Symbol: MDMA

Number of Outstanding Listed Securities: 91,724,217

Date: May 3, 2024

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

PharmAla continues to develop its two primary business lines: manufacturing and development of GMP MDMA for sales to clinical trial practitioners and the development of novel MDXX compounds.

PharmAla's research-and-development program also continues. Preclinical data continues to be transmitted from the University of Arkansas.

In a press release dated April 5, 2024, Pharmala announced that, in another Australian first, its joint venture, Cortexa Pty. Ltd., is proud to have commenced batch manufacturing of GMP LaNeo® MDMA 40mg capsules to support both clinical trials and clinical use under the TGA's Authorised Prescriber pathway.

In a press release dated April 10, 2024, Pharmala announced its intention to complete a non-brokered private placement offering of units of the Company (each, a "Unit") at a price of \$0.18 per Unit for aggregate gross proceeds of up to \$750,000.

In a press release dated April 19, 2024, Pharmala announced that further to its press release dated April 10, 2024, the Company has closed its previously announced non-brokered private placement offering effective today (the "Closing Date") through the issuance of 4,166,665 Units for gross proceed of \$750,000.

2. Provide a general overview and discussion of the activities of management.

In addition to the work described above, PharmAla continues development of novel analogs of MDMA. Management is active in growing the sales funnel for MDMA clinical trial supplies under the leadership of David Purcell. Shane Morris, COO, continues to work towards GMP production of MDMA. Harpreet Kaur directs the research program, as well as developing ICH materials supporting MDMA sales.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

PharmAla has completed initial manufacturing of its first clinical-grade MDMA Active Pharmaceutical Ingredient. Release testing has proven successful, and the product is now available for sale to qualified customers, subject to Health Canada Export Permitting.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no additional products or services discontinued during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See item #1

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No transactions or contracts were terminated or expired during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

No acquisitions were made during the period.

8. Describe the acquisition of new customers or loss of customers.

No acquisitions of new customers or loss of customers occurred during the period.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

In addition to the work described in item #1, PharmAla has issued a trademark filing for its generic MDMA product; The product will be known as LaNeo. PharmAla has filed several amendments to its provisional patents during the period; These filings currently constitute confidential company work product. PharmAla converted a major "constitution of matter" patent from provisional to full during the period; The patent contains formulations for 6 novel chemical entities with beneficial toxicology to traditional MDMA.

On March 20, PharmAla announced that the US Patent and Trademark Office had granted an allowance on its APA-001 molecular entity.

On March 26, PharmAla announced that the US Patent and Trademark Office had granted an allowance on its ALA-002 molecular entity.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated

length of lay-offs.

There were no changes to employees during the period.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no disputes with employees during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no substantive legal proceedings during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There were no changes to the company's indebtedness during the period.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common shares	4,166,665	Non-brokered private placement	General working capital
Warrants	2,083,331	Non-brokered private placement	General working capital
Common Shares	600,000	Shares for debt	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons.

16. Provide details of any changes in directors, officers or committee members.

There were no change in directors, officers or committee members.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There were no changes to major trends.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 3, 2024

Nicholas Kadysh
Name of Director or Senior
Officer

"Nicholas Kadysh"
Signature

Chief Executive Officer
Official Capacity

<i>Issuer Details</i> Name of Issuer Pharmala Biotech Holdings Inc.	For Month End April 2024	Date of Report YY/MM/DD 24/05/03
Issuer Address 82 Richmond Street East,		
City/Province/Postal Code Toronto, Ontario M5C 1P1	Issuer Fax No. ()	Issuer Telephone No. (855) 444-6362
Contact Name Nicholas Kadysh	Contact Position Director & CEO	Contact Telephone No. (855) 444-6362
Contact Email Address nick@pharmala.ca	Web Site Address https://pharmala.ca	